Skip to main content
. Author manuscript; available in PMC: 2022 May 9.
Published in final edited form as: Eur Urol. 2018 Oct 6;75(1):176–183. doi: 10.1016/j.eururo.2018.09.009

Table 2 –

Pre-SLND characteristics of 654 patients treated with salvage lymph node dissection for nodal recurrence of prostate cancer

Variable Overall population
(n = 654; 100%)
Time from RP to PSA rising, mo    19 (4–44)
HT administration at PSA rising, n (%)
 No  538 (82)
 Yes  116 (18)
Type of PET/CT tracer, n (%)
 11C-Choline  460 (70)
 68Ga-PSMA  194 (30)
Positive sites at PET/CT scan, n (%)
 Pelvic  534 (82)
 Retroperitoneal    62 (9)
 Both    58 (9)
Positive spots at PET/CT scan, n (%)
 1  332 (51)
 2  150 (23)
 3  112 (17)
 ≥4    60 (9)
Age at SLND, yr    66 (60–70)
PSA at SLND, ng/ml    2.1 (1.0–4.0)

HT = hormonal therapy; PET/CT = positron emission tomography/computed tomography; PSA = prostate-specific antigen; PSMA = prostate-specific membrane antigen; RP = radical prostatectomy; SLND = salvage lymph node dissection.

All values are medians (interquartile range) or frequencies (proportions).